Economics

This channel highlights factors that impact hospital and healthcare economics and revenue. This includes news on healthcare policies, reimbursement, marketing, business plans, mergers and acquisitions, supply chain, salaries, staffing, and the implementation of a cost-effective environment for patients and providers.

Thumbnail

Mass General’s radiology expansion plans ‘threaten’ healthcare affordability, state watchdog warns

Nearly $1.9M in upgrades at the system's flagship hospital would pull $4M in CT and MR revenues away from other healthcare players, according to a new analysis.

Thumbnail

USPSTF makes final ruling on screening asymptomatic adults for AFib

The organization issued a draft of its recommendation back in April, leaving time for public comments to be made. 

What radiology providers need to know about 2022 CPT coding updates

The American Medical Association has added nearly 250 new Current Procedural Terminology codes this year, but only a select few impact imaging.

UnitedHealthcare UHC UnitedHealth

Change Healthcare may sell off assets to close UnitedHealth deal, plus more vendor news

Also, Agfa to raise prices for its radiology solutions, Philips sees comparable sales decline, and Qure.ai scores an FDA clearance.

Thumbnail

Mark Cuban’s prescription drug company launches online pharmacy for affordable medications

The Mark Cuban Cost Plus Drug Company promises to bypass middlemen and "outrageous" markups for more than 100 medications.

Thumbnail

Only 21% of U.S. hospitals comply with price transparency mandate for shoppable imaging exams

The maximum charge for a contrast-enhanced pelvic CT was listed as $14,238 compared to a minimum of $193, exemplifying a wide variation in exam pricing.

Salt Lake City Utah

Private equity-backed Rayus Radiology reveals additional expansion plans

The growing imaging group is launching two new outpatient centers, ballooning its national total to 152 and counting. 

Thumbnail

Insurers spent millions on ivermectin prescriptions for COVID-19, despite the drug being ineffective

Private and Medicare insurers spent nearly $2.5 million on the anti-parasite drug during a single week in August 2021, researchers reported in JAMA Network Open.